Full
Outline
To provide reference for guiding individualized medication in epilepsy patients by retrospectively analyzing the therapeutic drug monitoring (TDM) of new antiseizure medications in the neurology department of a hospital.
Clinical data were collected from outpatients and inpatients in the neurology department (including pediatric neurology, neurology, and neurosurgery) of the hospital from January 2022 to August 2024, who underwent blood concentration monitoring of two new antiseizure medications, namely oxcarbazepine (OXC) and levetiracetam (LEV). The data included gender, age, antiseizure medication regimens, blood concentration measurements, clinical efficacy, and adverse drug reactions (ADRs). Statistical analysis was performed to compare whether there were differences in blood concentration levels among different age groups, genders, and combination therapies, as well as whether differences existed in clinical efficacy and ADR incidence across different blood concentration ranges.
Among the 414 TDM records, 206 cases were for OXC and 208 cases for LEV. Blood concentrations within the reference range were observed in 114 cases (69.9%) for OXC and 86 cases (41.35%) for LEV. A statistically significant difference in LEV blood concentrations was found among different age groups (P<0.05). The total incidence of ADRs in the OXC group (13.11%) was higher than that in the LEV group (0.27%), and ADR incidence in both groups was significantly correlated with blood concentration (P<0.05). However, no significant differences in blood concentrations were observed based on gender or combination therapy for either OXC or LEV (P>0.05). Additionally, no significant differences in clinical efficacy were found among different blood concentration groups (P>0.05).
Although the two new antiseizure medications, OXC and LEV, didn't show a significant positive correlation between blood concentration and clinical efficacy in the TDM process, their drug exposure levels are closely associated with the risk of ADRs. Blood concentration monitoring can provide valuable guidance for rational clinical drug use, ensuring safe and effective treatment for patients.
136
29
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
